DK0653439T3 - Stabiliserede oligonukleotider og anvendelse heraf - Google Patents

Stabiliserede oligonukleotider og anvendelse heraf

Info

Publication number
DK0653439T3
DK0653439T3 DK94117513T DK94117513T DK0653439T3 DK 0653439 T3 DK0653439 T3 DK 0653439T3 DK 94117513 T DK94117513 T DK 94117513T DK 94117513 T DK94117513 T DK 94117513T DK 0653439 T3 DK0653439 T3 DK 0653439T3
Authority
DK
Denmark
Prior art keywords
cys
asterisk
ala
thr
modified
Prior art date
Application number
DK94117513T
Other languages
Danish (da)
English (en)
Inventor
Gerhard Dr Kretzschmar
Irvin Dr Winkler
Eugen Dr Uhlmann
Anuschirwan Dr Peyman
Matthias Mag
Matthias Dr Helsberg
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK0653439T3 publication Critical patent/DK0653439T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK94117513T 1993-11-12 1994-11-07 Stabiliserede oligonukleotider og anvendelse heraf DK0653439T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4338704A DE4338704A1 (de) 1993-11-12 1993-11-12 Stabilisierte Oligonucleotide und deren Verwendung

Publications (1)

Publication Number Publication Date
DK0653439T3 true DK0653439T3 (da) 2004-08-09

Family

ID=6502470

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94117513T DK0653439T3 (da) 1993-11-12 1994-11-07 Stabiliserede oligonukleotider og anvendelse heraf

Country Status (12)

Country Link
US (1) US6348312B1 (fr)
EP (2) EP0653439B1 (fr)
JP (1) JP3558230B2 (fr)
AT (1) ATE265465T1 (fr)
AU (1) AU696635B2 (fr)
CA (1) CA2135591C (fr)
DE (2) DE4338704A1 (fr)
DK (1) DK0653439T3 (fr)
ES (1) ES2218522T3 (fr)
HK (1) HK1041888A1 (fr)
NZ (1) NZ264894A (fr)
PT (1) PT653439E (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
JP2001521520A (ja) 1997-04-11 2001-11-06 ジー．ディー．サール アンド カンパニー 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト
WO1998050540A1 (fr) * 1997-05-05 1998-11-12 Hoechst Marion Roussel Deutschland Gmbh NUCLEOTIDES ANTISENS MODIFIES COMPLEMENTAIRES D'UNE SECTION DU GENE HUMAIN Ha-Ras
EP0950709A1 (fr) * 1998-04-17 1999-10-20 Hoechst Marion Roussel Deutschland GmbH Oligonucléotides antisens pour inhiber l'expression de la sous-unité alphaV de l'intégrine
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP0979869A1 (fr) * 1998-08-07 2000-02-16 Hoechst Marion Roussel Deutschland GmbH Oligonucléotides courts pour inhiber l'expression de VEGF
EP0978561A1 (fr) * 1998-08-07 2000-02-09 Hoechst Marion Roussel Deutschland GmbH Oligonucléotides antisens pour inhiber l'expression du VEGF
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
WO2002066092A2 (fr) * 2001-02-23 2002-08-29 Angiogene Inc. Dispositif de diffusion de medicaments par elution pour le traitement de troubles vasculaires
DE10159904A1 (de) * 2001-12-06 2003-07-03 Adnagen Ag Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
BR0315053A (pt) * 2002-10-03 2005-08-09 Targegen Inc Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
JP2006512927A (ja) * 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
US20090280567A1 (en) * 2004-02-06 2009-11-12 Dharmacon, Inc. Stabilized sirnas as transfection controls and silencing reagents
EP2123759B1 (fr) * 2004-02-06 2014-01-15 Thermo Fisher Scientific Biosciences Inc. ARN stabilisés en tant que contrôles de la transfection et réactifs silencieux
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US7456176B2 (en) * 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US7935811B2 (en) * 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
US20060223777A1 (en) * 2005-03-29 2006-10-05 Dharmacon, Inc. Highly functional short hairpin RNA
CA2611720A1 (fr) * 2005-06-08 2006-12-14 Targegen, Inc. Methodes et preparations pour le traitement de troubles oculaires
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
PT1991678E (pt) * 2006-02-15 2015-11-25 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleótidos
WO2007127366A2 (fr) * 2006-04-25 2007-11-08 Targegen, Inc. Inhibiteurs de kinases et leurs procédés d'utilisation
US8809514B2 (en) * 2006-09-22 2014-08-19 Ge Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
CN101874111B (zh) * 2007-11-28 2013-06-05 国立大学法人东京医科齿科大学 利用内源性乳糜微粒递送用于抑制靶基因表达的核酸的体系
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2012008465A1 (fr) * 2010-07-16 2012-01-19 ナパジェン ファーマ，インコーポレテッド Complexe (acide nucléique)-polysaccharide
WO2012027206A1 (fr) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. Agents à base d'arni à un seul brin contenant une séquence intercalaire interne ne correspondant pas à un acide nucléique
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
WO2012060847A1 (fr) 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procédés de traitement de la myélofibrose
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
EP2586461A1 (fr) 2011-10-27 2013-05-01 Christopher L. Parks Particules virales dérivées d'un virus enveloppé
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP2781523A1 (fr) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Analogues oligonucléotides lipophiles
CN110997933B (zh) * 2017-08-02 2024-01-09 萨斯特德特股份有限两合公司 用于稳定无细胞核酸和细胞的方法和组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
EP0402402B1 (fr) * 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Inhibition du htlv-iii par des oligonucleotides exogenes
CA2029273A1 (fr) * 1989-12-04 1991-06-05 Christine L. Brakel Compose a base de nucleotide modifie
DE69133180T2 (de) * 1990-08-14 2003-07-24 Isis Pharmaceuticals, Inc. Beeinflussung der zelladhäsion durch oligonukleotide
JPH04154794A (ja) * 1990-10-15 1992-05-27 Yodogawa Seiyaku Kk アンチセンスオリゴデオキシリボヌクレオチドおよびそれを有効成分とするｈｉｖ活性阻害剤
WO1992020697A1 (fr) * 1991-05-10 1992-11-26 Hybridon, Inc. Oligonucleotides bloques au niveau de l'extremite 3'
EP0585399A4 (en) * 1991-05-23 1995-11-15 Univ Temple Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene
AU659482B2 (en) * 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
IL104461A (en) 1992-01-22 2001-05-20 Hoechst Ag Oligonucleotide analogs, their preparation and pharmaceutical compositions containing them
WO1993017125A1 (fr) * 1992-02-19 1993-09-02 Baylor College Of Medicine Modulation de la croissance cellulaire au moyen d'oligonucleotides
WO1994001551A1 (fr) * 1992-07-02 1994-01-20 United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede d'inhibition de la replication virale
AU678769B2 (en) * 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
DE4321946A1 (de) * 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
JP2000203104A (ja) * 1999-01-14 2000-07-25 Minolta Co Ltd プリンタ及びプリンタ制御装置
US7821415B1 (en) * 2008-04-04 2010-10-26 Kimberlin Denver K Pneumatically operated patient bed monitor

Also Published As

Publication number Publication date
JPH07194385A (ja) 1995-08-01
ATE265465T1 (de) 2004-05-15
US6348312B1 (en) 2002-02-19
EP0653439B1 (fr) 2004-04-28
JP3558230B2 (ja) 2004-08-25
DE59410371D1 (de) 2004-06-03
AU7779994A (en) 1995-05-18
AU696635B2 (en) 1998-09-17
HK1041888A1 (zh) 2002-07-26
DE4338704A1 (de) 1995-05-18
EP1182206A2 (fr) 2002-02-27
ES2218522T3 (es) 2004-11-16
EP0653439A3 (fr) 1995-10-25
CA2135591C (fr) 2010-10-26
EP0653439A2 (fr) 1995-05-17
EP1182206A3 (fr) 2002-08-21
PT653439E (pt) 2004-09-30
CA2135591A1 (fr) 1995-05-13
NZ264894A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
PT653439E (pt) Oligonucleotidos e sua aplicacao
FI932870A7 (fi) 2'-deoksi-2'2'-difluori-(4-substituoitu pyrimidiini)nukleosidejä, joilla on virusvastaista ja syöpävastaista aktiivisuutta, sekä välituotteita
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
ATE199906T1 (de) Phosphonat-nukleotid ester-derivate
DE69025529D1 (de) Weitere antivirale Pyrimidin-Nukleosiden
FI911193A0 (fi) Nya cc-1065-analoger med tvao cpi-subenheter.
FI920197A7 (fi) Viruksenvastaisia pyrimidiininukleosidejä
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
CA2002648A1 (fr) Derives 2'-halogenomethylidene, 2'-ethenylidene et 2'-ethynyle de cytidine, uridine et guanosine
DE69033730D1 (de) Pyrimidin- oder Triazinderivate und diese enthaltende herbizide Zusammenstellung
ATA10689A (de) Didesoxydehydrocarbocyclische nucleoside und deren verwendung
ATE186732T1 (de) (e)-2'-deoxy-2'-(fluormethylen)cytidin-monohydr t
DK630589D0 (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
ATE111477T1 (de) 2'-halomethyliden, 2'-ethenyliden und 2'-ethynyl- adenosinderivate.
ATE49976T1 (de) Modifizierte adeninegruppe enthaltende sonde, ihre herstellung und verwendungen.
FI944933A7 (fi) 7-disubstitoitu metyyli-4-okso-3H,5H-pyrrolo(3,2-d) pyrimidiini ja sit ä sisältäviä farmaseuttisia käyttöjä ja koostumuksia
ATE282627T1 (de) Pyrimidinnukleotid-vorläufer zur behandlung entzündlicher hepatitis
DE69034209D1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
DE3880083D1 (de) Nukleosid-derivate, insbesondere von 2'-deoxycytidin, und ihre anwendung in der synthese von oligonukleotiden.
DK0443471T3 (da) 2-Deoxy-2-methylidencytidin-dihydrat, fremgangsmåder til fremstilling heraf, samt præparater
ATE186731T1 (de) Anomere fluorribosylamine
IT8119758A0 (it) Derivati 2'-deossi-3',5'-di-o-alchilcarbonil-5-fluorouri dinici processo per la loro preparazione e agenti antitumorali che contengono i detti derivati.
BR9407232A (pt) Compostos de tiocarbamoíla
DE68912186D1 (de) UV-stabilisierte Acryl-Grundierungszusammensetzung.
DK0629209T3 (da) Sukkerderivater af makrolider